Global Chronic Obstructive Pulmonary Disease (COPD) Market Set to Surpass USD 33.19 Billion by 2033 Amid Rising Disease Burden and Therapeutic Demand | FMI

The global chronic obstructive pulmonary disease market is poised for substantial growth, with projections indicating a valuation of USD 21.58 billion in 2023. Driven by increasing alcohol consumption, tobacco use, and rapid urbanization, the demand for COPD-related therapies and products is expected to surge at a compound annual growth rate (CAGR) of 4.4% between 2023 and 2033. By the end of the forecast period, the market is projected to total around USD 33.19 billion.

According to the Global Burden of Disease study conducted by the Institute of Health Metrics and Evaluation in 2016, there were approximately 251 million cases of COPD worldwide. The World Health Organization (WHO) further reported that around 200 million individuals globally were diagnosed with COPD in 2016. This high prevalence underscores the growing burden of the disease and the urgent need for effective management solutions.

Track the Latest Market Developments: Request a Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-16215

Urbanization and Lifestyle Factors Driving Disease Prevalence

The risk of developing COPD is exacerbated by rapid urbanization, particularly in emerging economies across the Asia Pacific region. Increased exposure to environmental pollutants, lung irritants, and industrial emissions is contributing significantly to the rising incidence of the disease. Furthermore, WHO emphasizes that exposure to tobacco smoke—both first-hand and second-hand—remains the most significant risk factor for COPD worldwide.

The increasing adoption of smoking habits among millennials, paired with a surge in alcohol consumption, has further intensified the demand for COPD treatments. At the same time, growing awareness about the availability and effectiveness of generic medications is expected to support market expansion, making treatments more accessible and affordable for a broader segment of the population.

Economic Burden Highlighting the Need for Solutions

The economic impact of COPD is substantial and growing. According to the Centers for Disease Control and Prevention (CDC), the financial burden related to COPD in the United States was USD 32.1 billion in 2010, escalating to USD 49 billion by 2020. This continual rise in healthcare costs highlights the urgent need for innovative and cost-effective therapeutic solutions, thereby presenting significant growth opportunities for companies operating in the COPD market.

Key Takeaways

• North America Leads the COPD Market:

North America is expected to dominate the global COPD market with a 44% share in 2023, driven by a structured healthcare industry, strong reimbursement policies, ongoing R&D activities, rising smoking rates, and increasing air pollution.

• Asia Pacific Emerges as a Lucrative Market:

Asia Pacific is projected to hold the second-highest market share at 43% in 2023, fueled by a growing geriatric population, high disease incidence, and urbanization-induced air pollution, positioning the region for strong future growth.

• Combination Therapy to Stay Ahead:

The combination therapy segment leads the COPD market by drug class, accounting for 45% share and expected to grow at a CAGR of 4.3%, owing to higher treatment efficacy and increasing regulatory approvals.

• Chronic Bronchitis Dominates by Type:

Chronic bronchitis is the leading type within the COPD market, holding a 43% share in 2022 and expected to expand at a CAGR of 4.2%, largely due to rising prevalence among smokers and growing cases of airflow blockage.

• Retail Pharmacies Drive Distribution Growth:

Retail pharmacies captured 42% of the COPD market by distribution channel in 2022, with anticipated growth of 4.2% CAGR, supported by the expanding number of retail pharmacies and increased therapeutic dispensing.

Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report! https://www.futuremarketinsights.com/reports/chronic-obstructive-pulmonary-disease-copd-market

Competitive Landscape

The global COPD market is characterized by intense competition, with key players focusing on product innovation, strategic partnerships, and expanding their geographic footprint. Some of the leading players in the market include:

• Almirall
• AstraZeneca
• Boehringer Ingelheim International GmbH
• CHIESI Farmaceutici S.p.A.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc.
• Kyowa Hakko Kirin
• Mylan N.V.
• Novartis AG
• Orion Corporation
• Sanofi
• Sunovion Pharmaceuticals, Inc. (a Sumitomo Dainippon Pharma Co., Ltd. company)
• Teva Pharmaceutical Industries Ltd.
• Theravance Biopharma
• Verona Pharmaceuticals

Recent Strategic Developments

Innovation and clinical advancements remain at the forefront of the COPD market:

• In June 2022, Verona Pharma announced the completion of patient enrollment for its pivotal ENHANCE-1 trial, involving more than 800 subjects. The study aims to evaluate the efficacy of ensifentrine for the maintenance treatment of COPD. The company anticipates releasing top-line data for ENHANCE-1 by the end of 2022, with further insights from ENHANCE-2 expected in the third quarter of the year.
• In May 2022, Alembic Pharmaceuticals Ltd secured final approval from the U.S. Food & Drug Administration (USFDA) for its generic version of Arformoterol Tartrate inhalation solution, intended for the long-term treatment of bronchoconstriction in COPD patients. The approval covers a strength of 15 mcg (base)/2 mL unit-dose vial, adding a cost-effective therapeutic option to the U.S. market.

Segmentation Overview

The Chronic Obstructive Pulmonary Disease (COPD) market is segmented as follows:

• By Drug Class:
  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Others
• By Type:
  • Chronic Bronchitis
  • Emphysema
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Looking Ahead

The future of the COPD market looks promising as healthcare systems worldwide are increasingly focusing on early diagnosis, innovative treatment approaches, and public awareness campaigns to manage and mitigate the disease. With continued research, partnerships, and government support, the COPD market is expected to offer significant opportunities for both new entrants and established players over the next decade.

As COPD continues to pose a major global health challenge, the importance of innovation, affordability, and accessibility in treatment solutions will be paramount. Stakeholders investing in next-generation therapies, respiratory support devices, and comprehensive disease management programs are poised to make a significant impact in improving patient outcomes and capturing a larger share of the growing market.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube